PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III

Summary

This is a prospective, multi-center, open label, randomized control clinical trial evaluating the safety and efficacy of the Cordella™ Pulmonary Artery Sensor System in NYHA Class II-III Heart Failure Patients (PROACTIVE-HF-2 Trial). The study contains of 5 arms: NYHA II Cohort - To demonstrate safety and efficacy of the Cordella PA Sensor System in NYHA Class II HF patients, where patients have daily access to PAP data.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Heart Failure NYHA Class II
• Heart Failure NYHA Class III
• Heart Failure

Eligibility basics and study details

Study type

Interventional

Phase

Not applicable

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Endotronix, Inc.

Last updated on ClinicalTrials.gov

June 29, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites